Moderna与BioNTech的新冠mRNA疫苗使用N1-methylpseudouridine (1mψ)取代尿苷(U)进行核苷修饰,显著降低了mRNA的先天免疫应答。相比之下,作为mRNA三巨头之一的CureVac或许因为在mRNA分子修饰方面存在专利问题,所以采用了未经修饰的尿苷,通过序列优化...
美东时间本周四，美国新冠疫苗研发“领跑者”Moderna 在一项疫苗研发的关键专利案中败诉，这可能导致其正在研发的关键产品新冠疫苗 mRNA-1273 处于进退两难的境地，意味着 Moderna 可能要支付一定专利许可费或是被迫推迟 mRNA-1273 研发。Moderna 向美国商标专利局（The U.S. Patent and Trademark Office）申诉生物制药...
Best known, of course, are Moderna’s vaccines against infectious diseases, including mRNA-1273, the vaccine against the Novel coronavirus (SARS-CoV-2), which was granted emergency use authorization in December, 2020. In all, the company now has 21 programs in its pipeline with 11 in ...
mRNA-1273/Spikevax: COVID-19 vaccineKeytruda mRNA-1273.351: COVID-19 vaccine Beta variant XYZ XYZ XYZ Understand Moderna Inc portfolio and identify potential areas for collaborationRegister your interest History History section provides information on new products, mergers, acquisitions, expansions, appro...
Patent Rights The vast majority of mRNA vaccines have gone to wealthy countries and there have been sketchy plans to make these on African soil. But because Moderna said it wouldn't enforce the patent rights on its vaccine, scientists have been able to reverse engineer it via a special WHO-...